Skip to main content

Table 1 Characteristics of the included studies

From: Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis

Study Study design Location/period Follow-up (monthsa) No. of patients (male, %) Age, (yearsa) No. of stage
I/II/III/IV
No. of biliary drainage
(EBD/PBD)
No. of PVE Caudate lobectomy, % Main findings
Bednarsch et al. [28] Cohort study Germany/
2011–2016
28 (0–90) LH: 36 (63.9) 67 ± 9 1/0/23/12 35 (27/8) 0 100 3- and 5-year OS rate, LH = 62%,30% vs. RH = 51%,46%; R0, LH = 69.4% vs. RH = 75.6%
RH: 45 (68.9) 67 ± 11 2/6/23/14 46 (35/11) 37 100
Govil et al. [19] Cohort study India/
2009–2015
14 (3–64) LH: 23 (NR) 58 (20–74) 0/0/28/8 8 (0/8) 0 NR 2-year OS rate, LH = 39%vs. RH = 44%, R0, NR
RH: 13(NR) 6 (0/6) 0 NR
Hong et al. [29] Cohort study Korea/
2000–2018
NR LH: 82 (68.3) 63.46 ± 10.38 5/6/43/28 60 2 100 1-, 3-, and 5-year OS rate, LH = 87.3%, 38.2%, 24.7% vs. RH = 77.2%, 41.4%, 26.8%; R0, LH = 75.6% vs. RH = 72.8%
RH: 114 (66.7) 63.64 ± 8.72 4/13/75/22 93 45 100
Jo et al. [15] Cohort study Korea/
2010–2017
19 (1–97) LH: 24 (62.5) 71 (53–83) IV: 7 22(14/8) 0 100 1-, 3-, and 5-year OS rate, LH = 82.6%, 50.6%, 40.5% vs. RH = 69.3%, 48.5%, 37.7%; R0, LH = 75% vs. RH = 75.8%
RH: 33 (66.6) 66 (42–79) IV: 12 29(20/9) 6 100
Lee et al. [30] Cohort study Korea/
1995–2012
NR LH: 35 (57.1) 61.0 ± 8.1 IIIb:35 23 0 94.3 1-, 3-, and 5-year OS rate, LH = 80%, 47%, 35% vs. RH = 85%, 47%, 33%; R0, LH = 85.7% vs. RH = 82.5%
RH: 103 (66) 62.1 ± 9.2 IIIa: 103 71 24 86.4
Otto et al. [31] Cohort study Germany/
1998–2011
NR LH: 68 (75) 64 (39–83) 0/0/35/33 NR 0 100 1- and 5-year OS rate, LH = 72%, 22% vs. RH = 73%, 29%; R0, LH = 72.1% vs. RH = 82.4%
RH: 68 (66.2) 62 (44–82) 1/0/37/30 NR 4 100
Ratti et al. [32] Cohort study Italy/
2004–2014
23(3–98) LH: 44 (68.1) 59 (36–79) 1/17/13/13 23(6/16)b 0 97.7 3- and 5-year OS rate, LH = 49.5%, 35.3% vs. RH = 53.2%, 42.8%; R0, LH = 61.4% vs. RH = 75.4%
RH: 61 (50.8) 62 (41–82) 1/20/15/25 39(9/22)b 29 93.4
Shimizu et al. [11] Cohort study Japan/
1984–2008
NR LH: 88 (69.3) 67.0 ± 8.9 IIIb: 88 NR 5 100 1-, 3-, and 5-year OS rate, NR; R0, LH = 63.6% vs. RH = 69.1%
RH: 84 (56) 67.1 ± 8.0 IIIa +V: 84 NR 32 100
Sugiura et al. [33] Cohort study Japan/
2002–2013
NR LH: 12 (91.7) 65 (58–84) 2/10/0/0 NR 0 100 3- and 5-year OS rate, LH = 66.7%, 41.7% vs. RH = 70.8%, 49%; R0, NR
RH: 24 (75) 68 (37–81) 8/16/0/0 NR 24 100
Konstadoulakis et al. [34] Cohort study USA/
1988–2006
38 ± 30.4 LH: 29 NR NR NR 0 77.6 1-, 3-, and 5-year OS rate, LH = 66.7%, 33.3%, 21.7% vs. RH = 85%, 63.2%, 50%; R0, NR
RH: 20 NR NR NR 1
Yamanaka et al. [35] Cohort study Japan/
1980–1998
NR LH: 11 (54.5) 60 ± 11 NR NR NR 100 OS, HR, 0.53 95% CI, 0.02–15.24; R0, NR
RH: 14 (64.3) 55 ± 10 NR NR NR 93
  1. aSign indicates median (range); otherwise, data are expressed as mean ± SD
  2. bIn addition to EBD and PBD, biliary drainage also includes EBD + PBD
  3. Abbreviations: NR not reported in the text, EBD endoscopic biliary drainage, PBD percutaneous biliary drainage, PVE portal venous embolization